Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for myeloma patients with kidney issues: denosumab shows promise

NCT ID NCT02833610

First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 32 times

Summary

This study tested a drug called denosumab in 55 people with multiple myeloma and severe kidney problems. The goal was to see if it could help control bone damage caused by the cancer. Researchers measured changes in bone turnover markers and watched for side effects like low calcium levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Emory University Hospital

    Atlanta, Georgia, 30322, United States

  • Mass General/North Shore Cancer Center

    Danvers, Massachusetts, 01923, United States

  • Massachusetts general Hospital

    Boston, Massachusetts, 02114, United States

  • Newton Wellesley Hospital

    Newton, Massachusetts, 02462, United States

  • University Hospitals of Cleveland

    Cleveland, Ohio, 44106, United States

  • University of Rochester Medical Center

    Rochester, New York, 14642, United States

Conditions

Explore the condition pages connected to this study.